1
|
Prkačin I, Šamija I, Filipović N, Vucić M, Vučić M, Ferara N, Šitum M. Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ. J Clin Med 2024; 13:4799. [PMID: 39200941 PMCID: PMC11355897 DOI: 10.3390/jcm13164799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2024] [Revised: 08/07/2024] [Accepted: 08/12/2024] [Indexed: 09/02/2024] Open
Abstract
Background: In melanomas, mutations in the BRAF gene are common and their occurrence represents an early oncogenic event. Our goal was to determine and compare the frequency of BRAF gene mutations in dysplastic nevi (ND) and melanomas in situ (MIS), as well as whether there is a correlation between the presence of BRAF gene mutations and various anamnestic, clinical, and histopathologic variables. Methods: A total of 175 patients-106 with ND, 41 with MIS, and 28 with lentigo maligna (LM) were included in the study. DNA was extracted from tissue samples and analyzed using the competitive allele-specific TaqMan chain reaction by polymerase in real time to detect the presence of BRAF V600E and V600K mutations. The data were compared with anamnestic, clinical, and histopathological data. Results: There is a statistically significant correlation between the presence of BRAF mutation and the diagnosis of melanoma in situ (χ2 test, χ2 = 29.17, p < 0.0001). Patients with LM had a significantly lower incidence of BRAF mutations compared to patients with ND and MIS. There was a significant correlation between the presence of a BRAF mutation and tumor localization, as well as the age of the patient, but no statistically significant correlation between the presence of a BRAF mutation and sex, tumor size, or previous melanoma diagnosis. Conclusions: BRAF mutations in ND are essentially required; however, they are an insufficient oncogenic trigger for the development of melanoma. This research contributes to a better understanding of the etiopathogenesis of melanoma and the role of ND as possible precursor lesions.
Collapse
Affiliation(s)
- Ivana Prkačin
- Department of Dermatovenereology, Sestre Milosrdnice University Hospital Center, HR-10000 Zagreb, Croatia; (I.P.); (M.Š.)
| | - Ivan Šamija
- Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, HR-10000 Zagreb, Croatia;
| | - Nika Filipović
- Department of Dermatovenereology, Sestre Milosrdnice University Hospital Center, HR-10000 Zagreb, Croatia; (I.P.); (M.Š.)
| | - Matej Vucić
- Department of Biology, Faculty of Science, University of Zagreb, HR-10000 Zagreb, Croatia;
| | - Majda Vučić
- Clinical Department of Pathology and Cytology Ljudevit Jurak, Sestre Milosrdnice University Hospital Center, HR-10000 Zagreb, Croatia;
| | - Nikola Ferara
- Department of Dermatovenereology, Sestre Milosrdnice University Hospital Center, HR-10000 Zagreb, Croatia; (I.P.); (M.Š.)
| | - Mirna Šitum
- Department of Dermatovenereology, Sestre Milosrdnice University Hospital Center, HR-10000 Zagreb, Croatia; (I.P.); (M.Š.)
- School of Dental Medicine, University of Zagreb, HR-10000 Zagreb, Croatia
| |
Collapse
|
2
|
Dziankowska-Zaborszczyk E, Maniecka-Bryła I, Pikala M. Mortality Trends Due to Skin Melanoma in Poland in the Years 2000-2020. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:16118. [PMID: 36498192 PMCID: PMC9739595 DOI: 10.3390/ijerph192316118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 11/20/2022] [Accepted: 11/29/2022] [Indexed: 06/17/2023]
Abstract
The aim of this article is to assess mortality trends due to skin melanoma in Poland between the years 2000 and 2020, taking into account gender and place of residence (urban, rural). The subject of the analyses was data on 25,061 deaths that occurred between 2000 and 2020 due to skin melanoma (C43 according to ICD-10). Mortality rates due to this cancer, both crude (CDR) and standardised (SDR), were calculated. Trends on the calculated rates were analysed using the annual percentage change (APC) and average annual percentage change (AAPC), obtained from joinpoint regression models. Over the study period, the standardised death rate (SDR) due to skin melanoma in Poland increased from 3.60 to 4.03 per 100,000 population (AAPC = 1.1; p < 0.05), for urban residents it increased from 3.56 to 3.91 (APC = 1.2; p < 0.05) and for rural residents it increased from 3.00 to 4.24 (APC = 2.2; p < 0.05). A higher growth rate in terms of the SDR value between the years 2000 and 2020 was recorded in men compared to women and in rural when compared to urban residents. In Poland, mortality due to skin melanoma is on the rise. The early diagnosis of this cancer should become common practice in the Polish population.
Collapse
|
3
|
Huo Q, Yin Y, Liu F, Ma Y, Wang L, Qin G. Cell type identification from single-cell transcriptomes in melanoma. BMC Med Genomics 2021; 14:263. [PMID: 34784909 PMCID: PMC8596920 DOI: 10.1186/s12920-021-01118-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2021] [Accepted: 10/14/2021] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Single-cell sequencing approaches allow gene expression to be measured at the single-cell level, providing opportunities and challenges to study the aetiology of complex diseases, including cancer. METHODS Based on single-cell gene and lncRNA expression levels, we proposed a computational framework for cell type identification that fully considers cell dropout characteristics. First, we defined the dropout features of the cells and identified the dropout clusters. Second, we constructed a differential co-expression network and identified differential modules. Finally, we identified cell types based on the differential modules. RESULTS The method was applied to single-cell melanoma data, and eight cell types were identified. Enrichment analysis of the candidate cell marker genes for the two key cell types showed that both key cell types were closely related to the physiological activities of the major histocompatibility complex (MHC); one key cell type was associated with mitosis-related activities, and the other with pathways related to ten diseases. CONCLUSIONS Through identification and analysis of key melanoma-related cell types, we explored the molecular mechanism of melanoma, providing insight into melanoma research. Moreover, the candidate cell markers for the two key cell types are potential therapeutic targets for melanoma.
Collapse
Affiliation(s)
- Qiuyan Huo
- School of Computer Science and Technology, Xidian University, Xi’an, 710071 China
| | - Yu Yin
- School of Computer Science and Technology, Xidian University, Xi’an, 710071 China
| | - Fangfang Liu
- School of Computer Science and Technology, Xidian University, Xi’an, 710071 China
| | - Yuying Ma
- School of Computer Science and Technology, Xidian University, Xi’an, 710071 China
| | - Liming Wang
- School of Computer Science and Technology, Xidian University, Xi’an, 710071 China
| | - Guimin Qin
- School of Computer Science and Technology, Xidian University, Xi’an, 710071 China
| |
Collapse
|
4
|
Leeneman B, Schreuder K, Uyl-de Groot CA, van Akkooi ACJ, Haanen JBAG, Wakkee M, Franken MG, Louwman MWJ. Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. Eur J Cancer 2021; 154:111-119. [PMID: 34256280 DOI: 10.1016/j.ejca.2021.06.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/31/2021] [Accepted: 06/08/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To examine stage-specific trends in the incidence and survival of cutaneous melanoma in the Netherlands between 2003 and 2018, as well as the uptake of the sentinel lymph node biopsy (SLNB) and novel drugs during that period. METHODS Data were obtained from the nationwide population-based Netherlands Cancer Registry for all patients diagnosed with invasive primary cutaneous melanoma (n = 60,267). We presented age-standardized incidence rates, the proportion of patients with an SLNB, the proportion of patients who received a novel drug (for their primary diagnosis) and one- and five-year relative survival rates. RESULTS Between 2003 and 2018, the incidence rate increased from 10.9 to 23.9 for men and from 15.6 to 27.3 for women. This increase reflected the increasing incidence rate of patients with stage I and III. The proportion of patients with an SLNB increased from 23% to 64%. A reasonable increase was observed in the proportion of patients with a positive outcome (from 2% to 11%). For patients with stage IV, there was a shift from chemotherapy towards novel drugs as from 2013. The five-year relative survival rate increased from 81% to 92% for men and from 88% to 96% for women. This increase reflected the increasing five-year relative survival rate of patients with stage II, III, and IV. CONCLUSION We observed an increase in incidence for patients with stage I and III and an improvement in survival for patients with stage II, III and IV. These trends can be partly explained by the introduction of the SLNB and the novel drugs.
Collapse
Affiliation(s)
- Brenda Leeneman
- Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, the Netherlands.
| | - Kay Schreuder
- Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands
| | - Carin A Uyl-de Groot
- Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, the Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, the Netherlands
| | - Alexander C J van Akkooi
- Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands
| | - John B A G Haanen
- Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands
| | - Marlies Wakkee
- Department of Dermatology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands
| | - Margreet G Franken
- Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, the Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, the Netherlands
| | - Marieke W J Louwman
- Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands
| |
Collapse
|
5
|
Barbaric J, Laversanne M, Znaor A. Malignant melanoma incidence trends in a Mediterranean population following socioeconomic transition and war: results of age-period-cohort analysis in Croatia, 1989-2013. Melanoma Res 2017; 27:498-502. [PMID: 28800032 DOI: 10.1097/cmr.0000000000000385] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The aim of this study was to analyse trends of malignant melanoma incidence in Croatia for men and women of different age groups by birth cohorts and time periods, and to interpret them in the context of national socioeconomic changes over time and the possible implications for future prevention in South-Eastern European postcommunist countries with high mortality rates. We used the Croatian National Cancer Registry data to analyse incidence trends of malignant melanoma of the skin (ICD-9 code 172 and ICD-10 code C43) in men and women aged 25-79 years by age-period-cohort modelling. Over the 25-year period, the incidence was increasing by 5.0% annually in men and 4.6% in women. The age-period model provided the best fit for data in both sexes, with steeply increasing incidence rates, followed by a stabilization after the 2000s. On the cohort scale, incidence rates increased in successive generations of men, whereas in women, the risk of malignant melanoma attenuated in recent cohorts. Even if some progress has been achieved in recent years, the increasing melanoma incidence without concomitant declines in mortality would indicate a need to rekindle prevention efforts in the country taking the specific socioeconomic context into account.
Collapse
Affiliation(s)
- Jelena Barbaric
- aAndrija Stampar School of Public Health, School of Medicine, University of Zagreb, Zagreb, Croatia bSection of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | | | | |
Collapse
|
6
|
Rivera A, Nan H, Li T, Qureshi A, Cho E. Alcohol Intake and Risk of Incident Melanoma: A Pooled Analysis of Three Prospective Studies in the United States. Cancer Epidemiol Biomarkers Prev 2016; 25:1550-1558. [PMID: 27909090 PMCID: PMC5137801 DOI: 10.1158/1055-9965.epi-16-0303] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Revised: 08/15/2016] [Accepted: 08/15/2016] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Alcohol consumption is associated with increased risk of numerous cancers, but existing evidence for an association with melanoma is equivocal. No study has evaluated the association with different anatomic locations of melanoma. METHODS We used data from three large prospective cohort studies to investigate whether alcohol intake was associated with risk of melanoma. Alcohol intake was assessed repeatedly by food-frequency questionnaires. A Cox proportional hazards model was used to calculate multivariate-adjusted hazard ratios (HRs). RESULTS A total of 1,374 cases of invasive melanoma were documented during 3,855,706 person-years of follow-up. There was an association between higher alcohol intake and incidence of invasive melanoma (pooled multivariate HR 1.14 [95% confidence interval (CI), 1.00-1.29] per drink/day; Ptrend = 0.04). Among alcoholic beverages, white wine consumption was associated with an increased risk of melanoma (pooled multivariate HR 1.13 [95% CI, 1.04-1.24] per drink/day; Ptrend <0.01) after adjusting for other alcoholic beverages. The association between alcohol consumption and melanoma risk was stronger for melanoma in relatively UV-spared sites (trunk) versus more UV-exposed sites (head, neck, or extremities). Compared with nondrinkers, the pooled multivariate-adjusted HRs for ≥20 g/day of alcohol were 1.02 (95% CI, 0.64-1.62; Ptrend = 0.25) for melanomas of the head, neck, and extremities and 1.73 (95% CI, 1.25-2.38; Ptrend = 0.02) for melanomas of the trunk. CONCLUSIONS Alcohol intake was associated with a modest increase in the risk of melanoma, particularly in UV-protected sites. IMPACT These findings further support American Cancer Society Guidelines for Cancer Prevention to limit alcohol intake. Cancer Epidemiol Biomarkers Prev; 25(12); 1550-8. ©2016 AACR.
Collapse
Affiliation(s)
| | - Hongmei Nan
- Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
| | - Tricia Li
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Abrar Qureshi
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
- Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island
- Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island
| | - Eunyoung Cho
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island
- Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island
| |
Collapse
|
7
|
Barbaric J, Sekerija M, Agius D, Coza D, Dimitrova N, Demetriou A, Safaei Diba C, Eser S, Gavric Z, Primic-Zakelj M, Zivkovic S, Zvolsky M, Bray F, Coebergh JW, Znaor A. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer 2016; 55:47-55. [PMID: 26773419 DOI: 10.1016/j.ejca.2015.11.019] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 10/23/2015] [Accepted: 11/18/2015] [Indexed: 11/27/2022]
Abstract
INTRODUCTION Most countries in South-Eastern Europe (SEE) have lower incidence, but higher mortality rates of malignant melanoma (MM) of the skin compared to North-Western Europe (NWE). We explored trends in MM incidence and mortality in SEE countries by sex and age and compared them with the trends in NWE. METHODS We obtained data on incident cases and deaths from MM (ICD-10 code C43) from 11 population-based cancer registries in Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Malta, Romania, Serbia, Slovakia, Slovenia and Turkey. We calculated age-specific rates for 25-49 ('young'), 50-69 ('middle aged') and 70+ years ('older') and estimated the average annual percent of change in incidence and mortality trends 2000-2010 according to age group and sex, using joinpoint regression analysis. FINDINGS The incidence rates of MM across the region were uniformly increasing. Significant increases in mortality rates were observed in middle aged men in Serbia and Bulgaria, middle aged women in Slovenia, older men in the Czech Republic, Serbia and Turkey, and older women in Slovenia and Serbia. INTERPRETATION While MM incidence rates were still increasing across SEE, mortality trends diverged and were less favourable than in NWE. Empowering cancer registration and improving the quality of incidence and mortality data will be essential for monitoring progress in MM control. In the context of prevention of melanoma, disparities in early detection appear to be widening the gap between SEE and NWE, while the provision of care to patients with advanced disease is likely to prove a challenge for regional healthcare budgets.
Collapse
Affiliation(s)
- Jelena Barbaric
- Agency for Quality and Accreditation in Health Care and Social Welfare, Department for Development, Research and Health Technology Assessment, Planinska 13, 10000 Zagreb, Croatia.
| | - Mario Sekerija
- Croatian National Cancer Registry, Croatian Institute of Public Health, Rockefellerova 7, 10000 Zagreb, Croatia.
| | - Dominic Agius
- Malta National Cancer Registry, Department for Health Information and Research, 95, G'Mangia Hill, Pieta, PTA 1313, Malta.
| | - Daniela Coza
- Regional Cancer Registry of Cluj, Oncological Institute 'Ion Chiricuta', Republicii Street 34-36, 400015 Cluj-Napoca, Romania.
| | - Nadya Dimitrova
- Bulgarian National Cancer Registry, National Oncology Hospital, 6, Plovdivsko Pole Street, 1756 Sofia, Bulgaria.
| | - Anna Demetriou
- Cyprus Cancer Registry-Health Monitoring Unit, Ministry of Health, 1 Prodromou Street & 17 Chilonos Street, 1448 Lefkosia, Cyprus.
| | - Chakameh Safaei Diba
- National Cancer Registry of Slovakia, National Health Information Center, Lazaretska 26, 81109 Bratislava, Slovakia.
| | - Sultan Eser
- Hacettepe University, Public Health Institute, Sıhhıye Campus, Sıhhıye, 06100 Ankara, Turkey; Izmir Cancer Registry, Izmir Public Health Directorate, Zubeyde Hanim Caddesi No:100, 35067 Karsiyaka, Izmir, Turkey.
| | - Zivana Gavric
- Cancer Registry of Republic of Srpska, The Public Health Institute Banja Luka, Jovan Ducic 1, 78 000 Banja Luka, Bosnia and Herzegovina.
| | - Maja Primic-Zakelj
- Cancer Registry of Republic of Slovenia, Oncology Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia.
| | - Snezana Zivkovic
- Cancer Registry of Central Serbia, Institute of Public Health of Serbia, Dr Subotica 5, 11000 Belgrade, Serbia.
| | - Miroslav Zvolsky
- Czech National Cancer Registry, Institute of Health Information and Statistics of the Czech Republic, Palackého nám. 4, PO Box 60, 128 01 Praha 2, Czech Republic.
| | - Freddie Bray
- Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 CEDEX 08 Lyon, France.
| | - Jan Willem Coebergh
- Department of Public Health, Erasmus University Medical Center, PO Box 2040 3000 CA Rotterdam, The Netherlands.
| | - Ariana Znaor
- Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 CEDEX 08 Lyon, France.
| |
Collapse
|
8
|
|